CD25 rewires oncogene signaling in AML and ALL, revealing druggable complexes and a bold strategy: push pathways into toxic ...

Accelerated review was enabled by the Commissioner’s National Priority Voucher Pilot Program, targeting high unmet need and ...

If these results are validated by prospective trials, it could become a valuable tool for oncologists to assess results ...

Dr. Pooja Ghatalia presents findings from RETAIN-2, a single-arm phase 2 non-randomized trial evaluating a ...

Adjuvant therapy with durvalumab (Imfinzi) and tremelimumab-actl (Imjudo) in patients with resected RCC was associated with early reductions in patient-reported quality of life (QoL), according to ...

Aggregating ‘negative’ immunotherapy trials can uncover reproducible immune perturbations that are missed in single studies, ...

Dr Fred Saad of the University of Montreal discusses the future direction of alpha emitter agents in the treatment of prostate cancer, emphasizing the logical progression of resea ...

At the 2026 ASCO Genitourinary Cancers Symposium, Fred Saad, MD, presented encouraging phase 1 data evaluating the ...

CD25 expression has long been recognized as an adverse prognostic marker in acute leukemias including acute myeloid leukemia ...

February 2026 proved to be a pivotal month for the oncology landscape, as the FDA green-lit several therapies targeting some ...

Around the same time, LITESPARK-022 further positioned the drug in the second-line setting in combination strategies.

A genome-wide cfDNA methylation enrichment method (cfMeDIP-seq) enables response monitoring using plasma alone, avoiding ...